Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: A Korean multicenter retrospective study

摘要: Background/Aims Infliximab is currently used for the treatment of moderate-to-severe ulcerative colitis (UC) with an inadequate response to conventional agents. The efficacy and safety infliximab in Korean patients UC were assessed. Methods This was a retrospective multicenter study including all adult who received at least one infusion UC. Short- long-term clinical outcomes adverse events therapy evaluated, predictors identified. Results A total 134 included. indications acute severe 28%, steroid-dependency 38%, steroid-refractoriness 33%, respectively. rates remission 87% 45% week 8. In multivariate analysis, we found significant 8: immunomodulator-naive (odds ratio [OR] = 4.89, 95% confidence interval [CI]: 1.44–16.66, P = 0.01), hemoglobin ≥ 11.5 g/dL (OR = 4.47, CI: 1.48–13.45, P = 0.008), C-reactive protein ≥ 3 mg/dL (OR = 4.77, 1.43–15.94, 2 (OR = 20.54, 2.40–175.71, P = 0.006). Long-term 71% 52%, respectively, mucosal healing only factor influencing response. Adverse related occurred 15% patients, most them mild transient. Conclusions Infliximab effective safe active Korea. No history previous immunomodulator use high baseline protein are independent good